Skip to main content
Erschienen in: International Journal of Clinical Oncology 2/2015

01.04.2015 | Original Article

Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study

verfasst von: Go Omura, Mizuo Ando, Yuki Saito, Kenya Kobayashi, Tatsuya Yamasoba, Takahiro Asakage

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Total pharyngolaryngectomy (TPL) is a conventional and standard surgical method for locoregional control of advanced hypopharyngeal cancer (HPC). This study aimed to define the clinicopathological prognostic factors of TPL by evaluating our surgical experience of TPL in the treatment of HPCs.

Methods

We retrospectively reviewed the clinical charts of patients with HPC who were treated between 1995 and 2011 at the University of Tokyo Hospital and enrolled 119 patients who underwent TPL as an initial curative treatment.

Results

The mean follow-up period was 46 months (range, 2–164 months). The 5-year overall survival (OS), disease-specific survival (DSS), locoregional control rates, and relapse-free survival for all patients were 44, 53, 76, and 50 %, respectively. In multivariate analysis, the number of ≥4 metastatic lymph nodes (LNs) was a significant poor prognostic factor for both OS and DSS (p = 0.03 and p = 0.01). Patients with moderate to severe comorbidities had poor prognoses for OS (p = 0.002). In addition, patients with the number of ≥4 metastatic LNs had a higher incidence of distant metastases (p < 0.0001).

Conclusions

The locoregional control rate following TPL was acceptable and the number of metastatic LNs was associated with the incidence of distant metastases.
Literatur
1.
Zurück zum Zitat Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355:949–955CrossRefPubMed Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355:949–955CrossRefPubMed
2.
Zurück zum Zitat Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715CrossRefPubMed Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715CrossRefPubMed
3.
Zurück zum Zitat Posner MR, Norris CM, Wirth LJ et al (2009) Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324—survival, surgery, and organ preservation. Ann Oncol 20:921–927CrossRefPubMed Posner MR, Norris CM, Wirth LJ et al (2009) Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324—survival, surgery, and organ preservation. Ann Oncol 20:921–927CrossRefPubMed
5.
Zurück zum Zitat Brockstein B, Haraf DJ, Rademaker AW et al (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy—a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15:1179–1186CrossRefPubMed Brockstein B, Haraf DJ, Rademaker AW et al (2004) Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy—a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15:1179–1186CrossRefPubMed
6.
Zurück zum Zitat Hilgers FJM, Ackerstaff AH, Balm AJM et al (1997) Development and clinical evaluation of a second-generation voice prosthesis (Provox2), designed for anterograde and retrograde insertion. Acta Otolaryngol 117:889–896CrossRefPubMed Hilgers FJM, Ackerstaff AH, Balm AJM et al (1997) Development and clinical evaluation of a second-generation voice prosthesis (Provox2), designed for anterograde and retrograde insertion. Acta Otolaryngol 117:889–896CrossRefPubMed
7.
Zurück zum Zitat Terada T, Saeki N, Toh K et al (2007) Voice rehabilitation with Provox2™ voice prosthesis following total laryngectomy for laryngeal and hypopharyngeal carcinoma. Auris Nasus Larynx 34:65–71CrossRefPubMed Terada T, Saeki N, Toh K et al (2007) Voice rehabilitation with Provox2™ voice prosthesis following total laryngectomy for laryngeal and hypopharyngeal carcinoma. Auris Nasus Larynx 34:65–71CrossRefPubMed
8.
Zurück zum Zitat Wang WL, Lee CT, Hwang TZ et al (2011) Risk factors for developing synchronous esophageal neoplasia in patients with head and neck cancer. Head Neck 33:77–81CrossRefPubMed Wang WL, Lee CT, Hwang TZ et al (2011) Risk factors for developing synchronous esophageal neoplasia in patients with head and neck cancer. Head Neck 33:77–81CrossRefPubMed
9.
Zurück zum Zitat Hamajima N, Takezaki T, Tajima K (2002) Allele frequencies of 25 polymorphisms pertaining to cancer risk for Japanese, Koreans and Chinese. Asian Pac J Cancer Prev 3:197–206PubMed Hamajima N, Takezaki T, Tajima K (2002) Allele frequencies of 25 polymorphisms pertaining to cancer risk for Japanese, Koreans and Chinese. Asian Pac J Cancer Prev 3:197–206PubMed
10.
Zurück zum Zitat Asakage T, Yokoyama A, Haneda T et al (2006) Genetic polymorphisms of alcohol and aldehyde dehydrogenases, and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell carcinoma. Carcinogenesis 28:865–874CrossRefPubMed Asakage T, Yokoyama A, Haneda T et al (2006) Genetic polymorphisms of alcohol and aldehyde dehydrogenases, and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell carcinoma. Carcinogenesis 28:865–874CrossRefPubMed
11.
Zurück zum Zitat Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27:387–404CrossRefPubMed Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27:387–404CrossRefPubMed
12.
Zurück zum Zitat Piccirillo JF (2000) Importance of comorbidity in head and neck cancer. Laryngoscope 110:593–602CrossRefPubMed Piccirillo JF (2000) Importance of comorbidity in head and neck cancer. Laryngoscope 110:593–602CrossRefPubMed
13.
Zurück zum Zitat Rogers SN, Aziz A, Lowe D et al (2005) Feasibility study of the retrospective use of the Adult Comorbidity Evaluation Index (ACE-27) in patients with cancer of the head and neck who had radiotherapy. Br J Oral Maxillofac Surg 43:511–512CrossRef Rogers SN, Aziz A, Lowe D et al (2005) Feasibility study of the retrospective use of the Adult Comorbidity Evaluation Index (ACE-27) in patients with cancer of the head and neck who had radiotherapy. Br J Oral Maxillofac Surg 43:511–512CrossRef
14.
Zurück zum Zitat Paleri V, Wight RG (2002) Applicability of the adult comorbidity evaluation—27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol 116:200–205PubMed Paleri V, Wight RG (2002) Applicability of the adult comorbidity evaluation—27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol 116:200–205PubMed
15.
Zurück zum Zitat Sanabria A, Carvalho AL, Vartanian JG et al (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14:1449–1457CrossRefPubMed Sanabria A, Carvalho AL, Vartanian JG et al (2007) Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 14:1449–1457CrossRefPubMed
16.
Zurück zum Zitat Ferrier MB, Spuesens EB, Le Cessie S et al (2005) Comorbidity as a major risk factor for mortality and complications in head and neck surgery. Arch Otolaryngol Head Neck Surg 131:27–32CrossRefPubMed Ferrier MB, Spuesens EB, Le Cessie S et al (2005) Comorbidity as a major risk factor for mortality and complications in head and neck surgery. Arch Otolaryngol Head Neck Surg 131:27–32CrossRefPubMed
17.
Zurück zum Zitat Homma A, Sakashita T, Oridate N et al (2010) Importance of comorbidity in hypopharyngeal cancer. Head Neck 32:148–153PubMed Homma A, Sakashita T, Oridate N et al (2010) Importance of comorbidity in hypopharyngeal cancer. Head Neck 32:148–153PubMed
18.
Zurück zum Zitat Pignon JP, le Maitre A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMed Pignon JP, le Maitre A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMed
19.
Zurück zum Zitat Theile DR, Robinson DW, Theile DE et al (1995) Free jejunal interposition reconstruction after pharyngolaryngectomy: 201 consecutive cases. Head Neck 17:83–88CrossRefPubMed Theile DR, Robinson DW, Theile DE et al (1995) Free jejunal interposition reconstruction after pharyngolaryngectomy: 201 consecutive cases. Head Neck 17:83–88CrossRefPubMed
20.
Zurück zum Zitat Bova R, Goh R, Poulson M et al (2005) Total pharyngolaryngectomy for squamous cell carcinoma of hypopharynx: a review. Laryngoscope 115:864–869CrossRefPubMed Bova R, Goh R, Poulson M et al (2005) Total pharyngolaryngectomy for squamous cell carcinoma of hypopharynx: a review. Laryngoscope 115:864–869CrossRefPubMed
21.
Zurück zum Zitat Chu PY, Wang LW, Chang SY et al (2004) Surgical treatment of squamous cell carcinoma of the hypopharynx: analysis of treatment results, failure patterns, and prognostic factors. J Laryngol Otol 118:443–449PubMed Chu PY, Wang LW, Chang SY et al (2004) Surgical treatment of squamous cell carcinoma of the hypopharynx: analysis of treatment results, failure patterns, and prognostic factors. J Laryngol Otol 118:443–449PubMed
22.
Zurück zum Zitat Triboulet JP, Mariette C, Chevailier D et al (2001) Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg 136:1164–1170CrossRefPubMed Triboulet JP, Mariette C, Chevailier D et al (2001) Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg 136:1164–1170CrossRefPubMed
23.
Zurück zum Zitat Rapoport A, Franco EL (1993) Prognostic factors and relative risk in hypopharyngeal cancer-related parameters concerning stage, therapeutics and evolution. Rev Paul Med 111:337–343PubMed Rapoport A, Franco EL (1993) Prognostic factors and relative risk in hypopharyngeal cancer-related parameters concerning stage, therapeutics and evolution. Rev Paul Med 111:337–343PubMed
24.
Zurück zum Zitat Baghi M, Bisdas S, Engels K et al (2007) Prognostic relevance of volumetric analysis in tumour specimens of hypopharyngeal cancer. Clin Otolaryngol 32:372–377CrossRefPubMed Baghi M, Bisdas S, Engels K et al (2007) Prognostic relevance of volumetric analysis in tumour specimens of hypopharyngeal cancer. Clin Otolaryngol 32:372–377CrossRefPubMed
25.
Zurück zum Zitat Cooper JS, Pajak TF, Forastiere AA et al (1998) Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck 20:588–594CrossRefPubMed Cooper JS, Pajak TF, Forastiere AA et al (1998) Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck 20:588–594CrossRefPubMed
26.
Zurück zum Zitat Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944CrossRefPubMed Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944CrossRefPubMed
27.
Zurück zum Zitat Cooper JS, Pajak TF, Forastiere AA et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Radiat Oncol Biol Phys 84:1198–1205CrossRef Cooper JS, Pajak TF, Forastiere AA et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Radiat Oncol Biol Phys 84:1198–1205CrossRef
28.
Zurück zum Zitat Leemans CR, Tiwari R, Nauta JJ et al (1993) Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71:452–456CrossRefPubMed Leemans CR, Tiwari R, Nauta JJ et al (1993) Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71:452–456CrossRefPubMed
29.
Zurück zum Zitat Alvi A, Johnson JT (1997) Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck 19:500–505CrossRefPubMed Alvi A, Johnson JT (1997) Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck 19:500–505CrossRefPubMed
30.
Zurück zum Zitat Jacobs JR, Ahmad K, Casiano R et al (1993) Implications of positive surgical margins. Laryngoscope 103:64–68CrossRefPubMed Jacobs JR, Ahmad K, Casiano R et al (1993) Implications of positive surgical margins. Laryngoscope 103:64–68CrossRefPubMed
Metadaten
Titel
Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study
verfasst von
Go Omura
Mizuo Ando
Yuki Saito
Kenya Kobayashi
Tatsuya Yamasoba
Takahiro Asakage
Publikationsdatum
01.04.2015
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 2/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-014-0709-z

Weitere Artikel der Ausgabe 2/2015

International Journal of Clinical Oncology 2/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.